Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Allogeneic induced pluripotent stem cell-derived motor neuron progenitor cells (iPSC-MNPCs) are a cellular therapeutic modality designed to address the loss of motor neurons in neurodegenerative conditions such as Amyotrophic Lateral Sclerosis (ALS) (Nizzardo et al., 2014, Human Molecular Genetics). These cells are generated by reprogramming adult somatic cells into a pluripotent state and then directionally differentiating them into specialized progenitors committed to the motor neuron lineage (Takahashi & Yamanaka, 2006, Cell). Unlike conventional drugs, iPSC-MNPCs do not interact with a single molecular receptor; instead, they act as a multi-functional replacement therapy. Their primary mechanism involves engraftment into the host spinal cord, where they differentiate into mature neurons, extend axons toward muscle targets, and integrate into the host's neural circuitry to restore motor function (Sivadasan et al., 2018, Progress in Brain Research). Furthermore, these cells provide a bio-factory effect, secreting various neurotrophic factors that enhance the survival of remaining endogenous motor neurons and modulate the local inflammatory environment (Goutman et al., 2019, Molecular Neurodegeneration). Clinical development of these therapies focuses on ensuring the safety of the cells, particularly regarding their purity and the absence of undifferentiated pluripotent cells that could cause tumors. Because these cells are allogeneic, they typically require the co-administration of immunosuppressive drugs to prevent host-versus-graft rejection. This approach represents a paradigm shift from slowing disease progression to potentially regenerating lost neural pathways.
The therapeutic effect is achieved through the physical replacement of degenerated motor neurons via engraftment and differentiation into mature neurons that integrate into host neural circuits, alongside the secretion of neurotrophic factors (e.g., BDNF, GDNF) to support endogenous cell survival and modulate neuroinflammation (Nizzardo et al., 2014; Sivadasan et al., 2018).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Allogeneic induced pluripotent stem cell-derived motor neuron progenitor cells (iPSC-MNPCs) (iPSC-MNPCs).